Grzegorz Gołuński

Grzegorz Gołuński

Auto-generated profile, based on publicly available information

Grzegorz Gołuński

Laboratory of Biophysics, Intercollegiate Faculty of Biotechnology UG-MUG, Abrahama 58, 80-307 Gdańsk, Poland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2016 in Nano Research
Verified
Journal Article
Closed access
PDF file
SPSvitlana Prylutska
Svitlana Prylutska
RPRostyslav Panchuk
Rostyslav Panchuk
GGGrzegorz Gołuński
Grzegorz Gołuński
LSLarysa Skivka
Larysa Skivka
Yuriy PrylutskyyYuriy Prylutskyy
Yuriy Prylutskyy
PSPeter Scharff
Peter Scharff
We formulated and analyzed a novel nanoformulation of the anticancer drug cisplatin (Cis) with C60 fullerene (C60+Cis complex) and showed its higher toxicity toward tumor cell lines in vitro when compared to Cis alone. The highest toxicity of the complex was observed in HL-60/adr and HL-60/vinc chemotherapy-resistant human leukemia cell sublines (resistant to Adriamycin and Vinculin, respectively). We discovered that the action of the C60+Cis complex is associated with overcoming the drug resistance of the tumor cell lines through observing an increased number of apoptotic cells in the Annexin V/PI assay. Moreover, in vivo assays with Lewis lung carcinoma (LLC) C57BL/6J male mice showed that the C60+Cis complex increases tumor growth inhibition, when compared to Cis or C60 fullerenes alone. Simultaneously, we conducted a molecular docking study and performed an Ames test. Molecular docking specifies the capability of a C60 fullerene to form van der Waals interactions with potential binding sites on P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP-1), and multidrug resistance protein 2 (MRP-2) molecules. The observed phenomenon revealed a possible mechanism to bypass tumor cell drug resistance by the C60+Cis complex. Additionally, the results of the Ames test show that the formation of such a complex diminishes the Cis mutagenic activity and may reduce the probability of secondary neoplasm formation. In conclusion, the C60+Cis complex effectively induced tumor cell death in vitro and inhibited tumor growth in vivo, overcoming drug resistance likely by the potential of the C60 fullerene to interact with P-gp, MRP-1, and MRP-2 molecules. Thus, the C60+Cis complex might be a potential novel chemotherapy modification.

8 August 2015 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
MGMariusz Grinholc
Mariusz Grinholc
ARAleksandra Rodziewicz
Aleksandra Rodziewicz
KFKatarzyna Forys
Katarzyna Forys
ARAleksandra Rapacka-Zdonczyk
Aleksandra Rapacka-Zdonczyk
Anna KawiakAnna Kawiak
Anna Kawiak
KBKrzysztof Piotr Bielawski
Krzysztof Piotr Bielawski
Bacterial cell envelope is generally accepted as the primary target for a photo-induced oxidative stress. It is plausible that DNA damage occurs during the antimicrobial photoinactivation. Here we investigate the correlation between DNA damage and photoinactivation by evaluating the level of RecA-based DNA repair system in Staphylococcus aureus. By using exogenous photosensitizers (new methylene blue (NMB), toluidine blue O (TBO), 5,10,15,20-tetrakis(1-methyl-4-pyridinio)porphyrin tetra(p-toluenesulfonate) (TMPyP), zinc phthalocyanine (ZnPc), Rose Bengal (RB)) and ALA-induced endogenous porphyrin-dependent blue light (405 nm), several outcomes were observed: (i) an increase of DNA damage (from gel electrophoresis in DNA damage assay), (ii) an increase of recA expression (luminescence assay in recA-lux strain), and (iii) an increase of RecA protein level (Western blotting). When recA expression was repressed by novobiocin, or abolished by deleting the gene, S. aureus susceptibility towards photoinactivation was increased at approximately a hundred-fold. The absence of RecA increases DNA damage to yield bactericidal effect. In novobiocin-resistant mutant (gyrB), as opposed to wild type, neither RecA protein level nor cell’s susceptibility was affected by photoinactivation (when novobiocin is present). This is to suggest that GyrB-dependent inhibition mediated recA repression. Therefore, we have established the role of RecA in DNA damage during photoinactivation. With the use of rifampicin mutation frequency and Ames tests, we demonstrated that photoinactivation did not increase S. aureus mutagenesis and potentially is not mutagenic toward eukaryotic cells. The results suggest that the treatment is considered safe. In conclusion, we provide an evidence that recA inhibitor may serve as therapeutic adjuvant for antimicrobial photoinactivation. Clinical relevance of our findings warrants further investigations.

3 September 2014 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
Yuriy PrylutskyyYuriy Prylutskyy
Yuriy Prylutskyy
Maxim EvstigneevMaxim Evstigneev
Maxim Evstigneev
IPI. S. Pashkova
I. S. Pashkova
DWDariusz Wyrzykowski
Dariusz Wyrzykowski
AWAnna Woziwodzka
Anna Woziwodzka
URU. Ritter
U. Ritter
Unusual thermodynamic properties of C60 fullerene complexation with antibiotic doxorubicin were observed and explained.

1 April 2018 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
ABAgnieszka Borowik
Agnieszka Borowik
Yuriy PrylutskyyYuriy Prylutskyy
Yuriy Prylutskyy
ŁKŁukasz Kawelski
Łukasz Kawelski
OKOlena Kyzyma
Olena Kyzyma
LBLeonid Bulavin
Leonid Bulavin
Jacek PiosikJacek Piosik
Jacek Piosik

1 April 2016 in Biochimie
Verified
Journal Article
Closed access
GGGrzegorz Gołuński
Grzegorz Gołuński
ABAgnieszka Borowik
Agnieszka Borowik
NDNatalia Derewońko
Natalia Derewońko
Anna KawiakAnna Kawiak
Anna Kawiak
MRMichał Rychłowski
Michał Rychłowski
Jacek PiosikJacek Piosik
Jacek Piosik

10 July 2018 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
GGGrzegorz Golunski
Grzegorz Golunski
AWAnna Woziwodzka
Anna Woziwodzka
Jacek PiosikJacek Piosik
Jacek Piosik
Background Pentoxifylline (PTX) is a drug commonly used in the treatment of intermittent claudication. However, numerous research groups report that PTX also may potentially be used in the anticancer therapy following one of the main trends in the nowadays medicine – combined anticancer therapy. Scope of Review Review concentrates on the reports revealing potential use of PTX in cancer treatment. Major Conclusions PTX is described to possess several properties which may be exploited in cancer treatment. The drug reportedly to not only have anticancer activity itself, but also increase cancer cells susceptibility to radiation therapy and, additionally, reduce long-term side effects of this therapy. What is more, numerous research groups report that PTX may increase anticancer potential of commonly used anticancer drugs such as cisplatin or doxorubicin as well as reduce side effects of these drugs. Significance PTX should be considered as potential drug in the combined anticancer therapy.